Dr. Andreas Wallnöfer Joins Optigo Biotherapeutics' Board of Directors
Optigo Biotherapeutics, an ophthalmology company, has announced that Dr. Andreas Wallnöfer is joining its Board of Directors as the company advances its lead program to IND-enabling studies.
“Andreas is exactly the strategic leader and industry veteran we were looking for,” said Dr. Henning Afflerbach, Chair of the Board of Optigo. “His singular blend of operational experience — from bench to boardroom — and his track record of guiding programs through to successful exits will be invaluable as we move into clinical development.”
Dr. Wallnöfer expressed his enthusiasm for Optigo's innovative approach, stating:
“Optigo’s Hyaluronic Acid (HA)-anchoring platform is one of the most promising innovations in retinal drug design that I’ve seen,”
Author's summary: Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board.
More News
- McDonald’s (MCD) Earnings Snapshot: Same-Store Sales, Checks, and Cost Trends
- Best of the Boro 2025 - Kidovations Educational Experience
- WWE 'Raw': Logan Paul, The Vision attack CM Punk, Jey Uso - UPI.com
- Will AI free us from work? | LSE IQ Podcast
- Red Kettle Ringer Alert: Bell County Needs Volunteers to Raise Crucial $125K
- Mexican Truck Driver Sentenced To 15 Years In Prison For Trying To Smuggle Hundreds Of Pounds Of Cocaine Into The U.S.
- Voaden on warpath to open Totnes banking hub
- Join the Totnes community composting workshop
- Best of the Boro 2025 - Lee, Hill & Johnston Insurors
- Pyjama Day raises over £420 for Totnes charity